Shares of Biogen Inc. (BIIB) traded 3.99 points or 1.44% higher at $281.23.The total intraday money flow for the shares came in at a disappointing $(-11.11) million. The total upticks amounted to $88.58 million and the total downticks were approximately $99.69 million, with the up/down ratio of 0.89. On a different note, the shares have seen 1.09% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $4.48 million in upticks and an outflow of $2.78 million in downticks. The up/down ratio for the block was found to be 1.61. The net money flow for the block transaction was $(1.7) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Biogen Inc. appreciated by 3.09% during the last five trading days but lost 0.67% on a 4-week basis. Biogen Inc. is up 0.54% in the last 3-month period. Year-to-Date the stock performance stands at -0.67%. Biogen Inc. (NASDAQ:BIIB) rose 1.61% or 4.45 points on Wednesday and made its way into the gainers of the day. After trading began at $278.98 the stock was seen hitting $282.07 as a peak level and $277.5101 as the lowest level. The stock ended up at $281.69. The daily volume was measured at 1,699,544 shares. The 52-week high of the share price is $333.65 and the 52-week low is $223.0211. The company has a market cap of $60,845 million.
Company has reported several Insider transactions to the SEC, on Jan 10, 2017, Robert W Pangia (director) sold 5,450 shares at 295.39 per share price.On Dec 5, 2016, Adriana Karaboutis (EVP, Tech, Bus. Sol & Corp Aff) sold 48 shares at 296.53 per share price.On Sep 26, 2016, Caroline Dorsa (director) sold 27,570 shares at 314.00 per share price.
Biogen Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $5.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.08. Analyst had a consensus of $4.96. The company had revenue of $2872.00 million for the quarter, compared to analysts expectations of $2939.36 million. The companys revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.50 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Raymond James on Dec 29, 2016 to Strong Buy, Raises Price Target to $ 386 from a previous price target of $375 .Company shares were Reiterated by Stifel on Dec 9, 2016 to Hold, Raises Price Target to $ 298 from a previous price target of $291 .Biogen Inc was Initiated by Mizuho on Nov 8, 2016 to Buy, Price Target of the shares are set at $290.Biogen Inc was Upgraded by Piper Jaffray to Overweight on Nov 7, 2016. Biogen Inc was Upgraded by Leerink Partners to Outperform on Nov 7, 2016.
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimers disease, lupus nephritis to neuropathic pain.